Denali Therapeutics(DE:4DN)
€17.95+-0.29 (+3.01%)
DE:4DN
Denali Therapeutics financials statements
€17.95
At close:+-0.29 (+3.01%)
Denali Therapeutics (4DN) Ratios
7 Followers
Denali Therapeutics Ratios
DE:4DN's free cash flow for Q3 2026 was $-118.45M. For the 2026 fiscal year, DE:4DN's free cash flow was decreased by $-1.01M and operating cash flow was $-117.44M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 |
| Quick Ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 |
| Cash Ratio | 2.09 | 1.71 | 1.63 | 0.60 | 0.78 |
| Solvency Ratio | -3.80 | -2.86 | -1.05 | -0.76 | -0.64 |
| Operating Cash Flow Ratio | -4.20 | -3.40 | -4.59 | -0.67 | -0.56 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 769.57M | $ 719.94M | $ 941.17M | $ 954.51M | $ 455.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.04 | 0.05 | 0.04 | 0.05 |
| Debt-to-Equity Ratio | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 |
| Debt-to-Capital Ratio | 0.03 | 0.04 | 0.05 | 0.05 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.13 | 1.12 | 1.12 | 1.40 | 1.46 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.21 | 0.30 | 0.38 | 0.48 | 0.53 |
| Net Debt to EBITDA | 0.34 | 0.26 | 0.42 | 0.48 | 0.80 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | 0.00% | 0.00% | -59.51% | -314.16% | -607.78% |
| EBITDA Margin | 0.00% | 0.00% | -54.45% | -304.58% | -590.12% |
| Operating Profit Margin | 0.00% | 0.00% | -59.51% | -314.16% | -607.78% |
| Pretax Profit Margin | 0.00% | 0.00% | -43.93% | -300.54% | -598.34% |
| Net Profit Margin | 0.00% | 0.00% | -43.94% | -300.56% | -597.15% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -43.94% | -300.56% | -597.15% |
| Net Income Per EBT | 100.02% | 100.02% | 100.02% | 100.01% | 99.80% |
| EBT Per EBIT | 92.27% | 86.74% | 73.82% | 95.66% | 98.45% |
| Return on Assets (ROA) | -44.77% | -30.77% | -12.59% | -22.32% | -20.69% |
| Return on Equity (ROE) | -50.56% | -34.38% | -14.09% | -31.27% | -30.20% |
| Return on Capital Employed (ROCE) | -53.07% | -38.31% | -18.28% | -31.08% | -28.83% |
| Return on Invested Capital (ROIC) | -52.59% | -37.95% | -18.16% | -30.87% | -28.62% |
| Return on Tangible Assets | -44.77% | -30.77% | -12.59% | -22.32% | -20.69% |
| Earnings Yield | -17.69% | -12.61% | -4.93% | -9.34% | -5.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 96.65 | 11.69 | 39.69 |
| Payables Turnover | 3.36 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 4.61 | 1.46 | 0.70 |
| Asset Turnover | 0.00 | 0.00 | 0.29 | 0.07 | 0.03 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.33 | 0.14 | 0.05 |
| Cash Conversion Cycle | -108.69 | 0.00 | 3.78 | 31.24 | 9.20 |
| Days of Sales Outstanding | 0.00 | 0.00 | 3.78 | 31.24 | 9.20 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 108.69 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 3.78 | 31.24 | 9.20 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.35 | -2.11 | -2.61 | -1.95 | -1.74 |
| Free Cash Flow Per Share | -2.41 | -2.21 | -2.70 | -2.09 | -1.81 |
| Dividend Paid and CapEx Coverage Ratio | -43.42 | -21.85 | -27.67 | -13.72 | -24.87 |
| Capital Expenditure Coverage Ratio | -43.42 | -21.85 | -27.67 | -13.72 | -24.87 |
| Operating Cash Flow Coverage Ratio | -11.23 | -7.14 | -6.85 | -4.05 | -3.30 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -1.08 | -2.26 | -4.34 |
| Free Cash Flow Yield | -14.57% | -10.85% | -12.58% | -7.52% | -4.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.56 | -7.93 | -20.30 | -10.71 | -18.65 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 8.92 | 32.19 | 111.38 |
| Price-to-Book (P/B) Ratio | 2.86 | 2.73 | 2.86 | 3.35 | 5.63 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.86 | -9.22 | -7.95 | -13.30 | -24.65 |
| Price-to-Operating Cash Flow Ratio | -7.02 | -9.64 | -8.23 | -14.27 | -25.64 |
| Price-to-Earnings Growth (PEG) Ratio | -0.36 | -0.06 | 0.34 | -1.22 | 0.04 |
| Enterprise Value Multiple | -5.48 | -6.54 | -15.96 | -10.09 | -18.08 |
| Enterprise Value | 2.73B | 3.23B | 2.87B | 3.33B | 5.19B |
| EV to EBITDA | -5.48 | -6.54 | -15.96 | -10.09 | -18.08 |
| EV to Sales | 0.00 | 0.00 | 8.69 | 30.73 | 106.67 |
| EV to Free Cash Flow | -6.46 | -8.87 | -7.75 | -12.70 | -23.61 |
| EV to Operating Cash Flow | -6.61 | -9.28 | -8.03 | -13.62 | -24.55 |
| Tangible Book Value Per Share | 5.78 | 7.48 | 7.50 | 8.30 | 7.92 |
| Shareholders’ Equity Per Share | 5.78 | 7.48 | 7.50 | 8.30 | 7.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 2.41 | 0.86 | 0.40 |
| Net Income Per Share | -2.92 | -2.57 | -1.06 | -2.60 | -2.39 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.84 | 0.74 | 0.96 | 0.98 |
| Research & Development to Revenue | 0.00 | 0.00 | 1.28 | 3.31 | 5.45 |
| SG&A to Revenue | 0.00 | 0.00 | 0.31 | 0.83 | 1.62 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.33 | 0.92 | 1.75 |
| Income Quality | 0.81 | 0.82 | 2.47 | 0.75 | 0.73 |
Currency in USD
